Pooled efficacy favored ravulizumab, improving QMG (MD –2.91) and MG-ADL (MD –2.64) after ~25 weeks, despite substantial between-study heterogeneity. Clinically meaningful MG-ADL response (≥2-point ...
Gefurulimab showed significant improvements in MG-ADL and QMG scores in the phase 3 PREVAIL trial, with early benefits sustained through week 26. Administered subcutaneously, gefurulimab offers ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results